Literature DB >> 23536563

Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma.

Shumei Song1, Dipen M Maru, Jaffer A Ajani, Chia-Hsin Chan, Soichiro Honjo, Hui-Kuan Lin, Arlene Correa, Wayne L Hofstetter, Marta Davila, John Stroehlein, Lopa Mishra.   

Abstract

TGF-β and Notch signaling pathways play important roles in regulating self-renewal of stem cells and gastrointestinal carcinogenesis. Loss of TGF-β signaling components activates Notch signaling in esophageal adenocarcinoma, but the basis for this effect has been unclear. Here we report that loss of TGF-β adapter β2SP (SPNB2) activates Notch signaling and its target SOX9 in primary fibroblasts or esophageal adenocarcinoma cells. Expression of the stem cell marker SOX9 was markedly higher in esophageal adenocarcinoma tumor tissues than normal tissues, and its higher nuclear staining in tumors correlated with poorer survival and lymph node invasion in esophageal adenocarcinoma patients. Downregulation of β2SP by lentivirus short hairpin RNA increased SOX9 transcription and expression, enhancing nuclear localization for both active Notch1 (intracellular Notch1, ICN1) and SOX9. In contrast, reintroduction into esophageal adenocarcinoma cells of β2SP and a dominant-negative mutant of the Notch coactivator mastermind-like (dnMAN) decreased SOX9 promoter activity. Tumor sphere formation and invasive capacity in vitro and tumor growth in vivo were increased in β2SP-silenced esophageal adenocarcinoma cells. Conversely, SOX9 silencing rescued the phenotype of esophageal adenocarcinoma cells with loss of β2SP. Interaction between Smad3 and ICN1 via Smad3 MH1 domain was also observed, with loss of β2SP increasing the binding between these proteins, inducing expression of Notch targets SOX9 and C-MYC, and decreasing expression of TGF-β targets p21(CDKN1A), p27 (CDKN1B), and E-cadherin. Taken together, our findings suggest that loss of β2SP switches TGF-β signaling from tumor suppression to tumor promotion by engaging Notch signaling and activating SOX9. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23536563      PMCID: PMC3745222          DOI: 10.1158/0008-5472.CAN-12-1962

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment.

Authors:  Steven R DeMeester
Journal:  Ann Surg Oncol       Date:  2006-01-01       Impact factor: 5.344

2.  Purification of proteins fused to glutathione S-transferase.

Authors:  Sandra Harper; David W Speicher
Journal:  Methods Mol Biol       Date:  2011

3.  Sox9 expression marks a subset of CD24-expressing small intestine epithelial stem cells that form organoids in vitro.

Authors:  Adam D Gracz; Sendhilnathan Ramalingam; Scott T Magness
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-02-25       Impact factor: 4.052

4.  Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness.

Authors:  P Zhang; Y Yang; R Nolo; P A Zweidler-McKay; D P M Hughes
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

Review 5.  Notch signaling: emerging molecular targets for cancer therapy.

Authors:  Ling Yin; Omaida C Velazquez; Zhao-Jun Liu
Journal:  Biochem Pharmacol       Date:  2010-03-31       Impact factor: 5.858

Review 6.  Notch signaling in gastrointestinal tract (review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Oncol       Date:  2007-01       Impact factor: 5.650

7.  Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression.

Authors:  V Katuri; Y Tang; E P Reddy; C Li; W Jogunoori; C-X Deng; A Rashid; A N Sidawy; S Evans; B Mishra; L Mishra
Journal:  Oncogene       Date:  2006-03-23       Impact factor: 9.867

8.  Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.

Authors:  Uma Raju; Hisanori Ariga; Masashi Koto; Xueguan Lu; Jessica Pickett; David Valdecanas; Kathryn A Mason; Luka Milas
Journal:  Radiother Oncol       Date:  2006-08-14       Impact factor: 6.280

9.  Regulation of the human SOX9 promoter by Sp1 and CREB.

Authors:  Sonsoles Piera-Velazquez; David F Hawkins; Mary Kate Whitecavage; David C Colter; David G Stokes; Sergio A Jimenez
Journal:  Exp Cell Res       Date:  2007-01-08       Impact factor: 3.905

10.  Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation.

Authors:  B A Onwuegbusi; A Aitchison; S-F Chin; T Kranjac; I Mills; Y Huang; P Lao-Sirieix; C Caldas; R C Fitzgerald
Journal:  Gut       Date:  2005-12-20       Impact factor: 23.059

View more
  33 in total

Review 1.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

2.  Editorial on role of p53 in esophageal cancer from a meta-analysis of 16 studies by Fisher et al.

Authors:  Francesca Steccanella; Antonio Costanzo; Fausto Petrelli
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

3.  Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer.

Authors:  Andrew E Blum; Srividya Venkitachalam; Durgadevi Ravillah; Aruna K Chelluboyina; Ann Marie Kieber-Emmons; Lakshmeswari Ravi; Adam Kresak; Apoorva K Chandar; Sanford D Markowitz; Marcia I Canto; Jean S Wang; Nicholas J Shaheen; Yan Guo; Yu Shyr; Joseph E Willis; Amitabh Chak; Vinay Varadan; Kishore Guda
Journal:  Gastroenterology       Date:  2019-02-12       Impact factor: 22.682

4.  Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties.

Authors:  Shumei Song; Jaffer A Ajani; Soichiro Honjo; Dipen M Maru; Qiongrong Chen; Ailing W Scott; Todd R Heallen; Lianchun Xiao; Wayne L Hofstetter; Brian Weston; Jeffrey H Lee; Roopma Wadhwa; Kazuki Sudo; John R Stroehlein; James F Martin; Mien-Chie Hung; Randy L Johnson
Journal:  Cancer Res       Date:  2014-06-06       Impact factor: 12.701

5.  TGF-β1 pathway affects the protein expression of many signaling pathways, markers of liver cancer stem cells, cytokeratins, and TERT in liver cancer HepG2 cells.

Authors:  Xin-Hong Wang; Ming-Na Liu; Xun Sun; Chun-Huan Xu; Jing Liu; Jing Chen; Rui-Ling Xu; Bao-Xin Li
Journal:  Tumour Biol       Date:  2015-10-13

6.  A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.

Authors:  Shumei Song; Min Xie; Ailing W Scott; Jiankang Jin; Lang Ma; Xiaochuan Dong; Heath D Skinner; Randy L Johnson; Sheng Ding; Jaffer A Ajani
Journal:  Mol Cancer Ther       Date:  2017-11-22       Impact factor: 6.261

7.  The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.

Authors:  Shumei Song; Soichiro Honjo; Jiankang Jin; Shih-Shin Chang; Ailing W Scott; Qiongrong Chen; Neda Kalhor; Arlene M Correa; Wayne L Hofstetter; Constance T Albarracin; Tsung-Teh Wu; Randy L Johnson; Mien-Chie Hung; Jaffer A Ajani
Journal:  Clin Cancer Res       Date:  2015-03-04       Impact factor: 12.531

8.  Expression and Therapeutic Potential of SOX9 in Chordoma.

Authors:  Hua Chen; Cassandra C Garbutt; Dimitrios Spentzos; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Clin Cancer Res       Date:  2017-06-12       Impact factor: 12.531

9.  ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.

Authors:  J A Ajani; X Wang; S Song; A Suzuki; T Taketa; K Sudo; R Wadhwa; W L Hofstetter; R Komaki; D M Maru; J H Lee; M S Bhutani; B Weston; V Baladandayuthapani; Y Yao; S Honjo; A W Scott; H D Skinner; R L Johnson; D Berry
Journal:  Mol Oncol       Date:  2013-10-28       Impact factor: 6.603

10.  Signaling Cascades Governing Cdc42-Mediated Chondrogenic Differentiation and Mensenchymal Condensation.

Authors:  Jirong R Wang; Chaojun J Wang; Chengyun Y Xu; Xiaokai K Wu; Dun Hong; Wei Shi; Ying Gong; Haixiao X Chen; Fanxin Long; Ximei M Wu
Journal:  Genetics       Date:  2016-01-06       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.